Immatics Biotechnologies Granted U.S. Patent #11559550: Peptides And Combination Of Peptides For Use In Immunotherapy Against Leukemias And Other Cancers
https://www.scribd.com/document/621632292/IMTX-Patent
Immatics Biotechnologies Granted U.S. Patent #11554164: A*03 Restricted Peptides For Use In Immunotherapy Against Cancers And Related Methods
https://www.scribd.com/document/620318568/IMTX-Patent
Immatics Biotechnologies Granted U.S. Patent #11542303: Peptides and combination thereof for use in the immunotherapy against cancers
https://www.scribd.com/document/617594407/IMTX-Patent
12 Health Care Stocks Moving In Monday’s Pre-Market Session
Gainers Cosmos Holdings (NASDAQ:COSM) stock increased by 20.5% to $0.52 during Monday’s pre-market session. The company’s market cap…
Immatics Biotechnologies Granted U.S. Patent #11498948 Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
https://www.scribd.com/document/607726122/IMTX-Patent
Why Immunic Shares Jumped By Around 57%; Here Are 73 Biggest Movers From Yesterday
Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares climbed 71% to close at $2.12 on Monday after the company announced it has received its largest single purchase order for LinearDNA™ valued above the mid-six-figures.
Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday’s Mid-Day Session
Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the mid-six-figures.
Immatics Reports Interim Clinical Data Update On ACTengine IMA203 TCR-T Monotherapy Targeting PRAME
Clinical validation of PRAME as multi-tumor target with large potential for TCR-based therapies: confirmed responses in different solid cancers, in patients with high and low PRAME expression
Update covers data from
Immatics Biotechnologies Granted U.S. Patent #11,440,947 ‘Peptides and Combination of Peptides for Use in Immunotherapy Against Various Tumors
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.htm&r=5421&f=G&l=50&d=PTXT&p=109&S1=20220913&OS=20220913&RS=20220913
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.